CO4900057A1 - Dihidrato d de olanzapina - Google Patents

Dihidrato d de olanzapina

Info

Publication number
CO4900057A1
CO4900057A1 CO97055058A CO97055058A CO4900057A1 CO 4900057 A1 CO4900057 A1 CO 4900057A1 CO 97055058 A CO97055058 A CO 97055058A CO 97055058 A CO97055058 A CO 97055058A CO 4900057 A1 CO4900057 A1 CO 4900057A1
Authority
CO
Colombia
Prior art keywords
methyl
olanzapine
dihydrate
olanzapine dihydrate
benzodiazepine
Prior art date
Application number
CO97055058A
Other languages
English (en)
Inventor
Samuel Dean Larsen
John Richard Nichols
Susan Marie Reutzel
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21832112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4900057(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4900057A1 publication Critical patent/CO4900057A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

El polimorfo Dihidrato D de la olanzapina (2-metil-4-(4-metil-d1-piperazinil)-10H-tieno[2,3-b][1,5]benzodiacepina), de fórmula (I) que tiene un patrón típico de difracción de rayos X en pulverizado según se representa por los siguientes espaciamientos interplanares (d) establecidos en la Tabla 1: Tabla 1 9,4511 7,7098 7,4482 6,9807 6,5252 5,7076 5,5539 5,223 4,9803 4,8908 4,784 4,6947 4,4271 4,3956 4,3492 4,2834 4,1156 3,7837 3,7118 3,5757 3,482 3,3758 3,3274 3,2413 3,1879 3,135 3,0979 3,016 2,9637 2,907 2,8256 2,7914 2,7317 2,6732 2,5863
CO97055058A 1996-09-23 1997-09-22 Dihidrato d de olanzapina CO4900057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2648696P 1996-09-23 1996-09-23

Publications (1)

Publication Number Publication Date
CO4900057A1 true CO4900057A1 (es) 2000-03-27

Family

ID=21832112

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97055058A CO4900057A1 (es) 1996-09-23 1997-09-22 Dihidrato d de olanzapina

Country Status (35)

Country Link
US (1) US6251895B1 (es)
EP (1) EP0831097B1 (es)
JP (1) JP2001500878A (es)
KR (1) KR100516088B1 (es)
CN (1) CN1146567C (es)
AR (1) AR009801A1 (es)
AT (1) ATE221074T1 (es)
AU (1) AU720366B2 (es)
BR (1) BR9711541A (es)
CA (1) CA2266444C (es)
CO (1) CO4900057A1 (es)
CZ (1) CZ299247B6 (es)
DE (1) DE69714165T2 (es)
DK (1) DK0831097T3 (es)
EA (1) EA001881B1 (es)
EG (1) EG23815A (es)
ES (1) ES2180899T3 (es)
HK (1) HK1009809A1 (es)
HU (1) HU226167B1 (es)
ID (1) ID21924A (es)
IL (1) IL128956A0 (es)
MY (1) MY125467A (es)
NO (1) NO323979B1 (es)
NZ (1) NZ334346A (es)
PE (1) PE110298A1 (es)
PL (1) PL194074B1 (es)
PT (1) PT831097E (es)
RS (1) RS49597B (es)
SI (1) SI0831097T1 (es)
SV (1) SV1997000079A (es)
TR (1) TR199900639T2 (es)
TW (1) TW518335B (es)
UA (1) UA56184C2 (es)
WO (1) WO1998011893A1 (es)
ZA (1) ZA978512B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
CA2344873A1 (en) * 1998-09-30 2000-04-06 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
CA2395774C (en) * 1999-12-28 2009-09-15 Cipla Limited New polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
IL154688A0 (en) * 2000-08-31 2003-09-17 Reddys Lab Ltd Dr Hydrates of olanzapine and processes for the preparation thereof
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
CA2464306A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
SI1513846T1 (sl) 2002-05-31 2011-11-30 Sandoz Ag Postopek za pripravo olanzapina form I
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003300324A1 (en) * 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2005049090A2 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
WO2006006185A1 (en) * 2004-07-14 2006-01-19 Shasun Chemicals And Drugs Limited Improved process for making form i of olanzapine.
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE112005000641T5 (de) 2004-09-06 2007-09-06 Shasun Chemicals and Drugs Ltd., Chennai Neues Verfahren zur Herstellung einer pharmazeutisch reinen polymorphen Form I von Olanzapin
JP5215666B2 (ja) 2004-09-29 2013-06-19 バイエル・ファルマ・アクチェンゲゼルシャフト Ｂａｙ４３−９００６トシレートの熱力学的に安定な形態
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN101106972A (zh) * 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7932249B2 (en) 2005-01-05 2011-04-26 Eli Lilly And Company Olanzapine pamoate dihydrate
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US7834176B2 (en) * 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US8173637B2 (en) * 2008-07-24 2012-05-08 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP2016027003A (ja) * 2012-11-20 2016-02-18 大蔵製薬株式会社 長期間安定なオランザピンの水性医薬製剤
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302716A (en) * 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
PT582368E (pt) * 1992-05-29 2001-05-31 Lilly Co Eli Derivados de tienobenzodiazepina para o tratamento de doencas de cns
BR9508136A (pt) 1994-06-28 1997-11-25 Grace W R & Co Bolsas tendo remendos protetores
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine

Also Published As

Publication number Publication date
IL128956A0 (en) 2000-02-17
CZ98999A3 (cs) 1999-08-11
PL332541A1 (en) 1999-09-13
EA199900325A1 (ru) 1999-08-26
ES2180899T3 (es) 2003-02-16
AR009801A1 (es) 2000-05-03
EA001881B1 (ru) 2001-10-22
YU15499A (sh) 2000-03-21
PE110298A1 (es) 1999-01-18
CN1234738A (zh) 1999-11-10
HUP0000065A2 (hu) 2000-06-28
US6251895B1 (en) 2001-06-26
HUP0000065A3 (en) 2000-11-28
SV1997000079A (es) 1999-01-13
NO991339L (no) 1999-03-19
PL194074B1 (pl) 2007-04-30
AU720366B2 (en) 2000-06-01
UA56184C2 (uk) 2003-05-15
NZ334346A (en) 2000-05-26
EP0831097B1 (en) 2002-07-24
EG23815A (en) 2007-08-19
EP0831097A2 (en) 1998-03-25
WO1998011893A1 (en) 1998-03-26
SI0831097T1 (en) 2003-02-28
CZ299247B6 (cs) 2008-05-28
JP2001500878A (ja) 2001-01-23
ZA978512B (en) 1999-03-23
PT831097E (pt) 2002-10-31
DE69714165D1 (de) 2002-08-29
RS49597B (sr) 2007-06-04
HU226167B1 (hu) 2008-05-28
MY125467A (en) 2006-08-30
CN1146567C (zh) 2004-04-21
NO991339D0 (no) 1999-03-19
KR20000048519A (ko) 2000-07-25
ATE221074T1 (de) 2002-08-15
HK1009809A1 (en) 1999-06-11
DK0831097T3 (da) 2002-09-02
DE69714165T2 (de) 2003-01-23
KR100516088B1 (ko) 2005-09-22
TR199900639T2 (xx) 1999-06-21
NO323979B1 (no) 2007-07-30
EP0831097A3 (en) 1998-04-29
AU4424197A (en) 1998-04-14
CA2266444C (en) 2007-01-09
CA2266444A1 (en) 1998-03-26
BR9711541A (pt) 1999-08-24
TW518335B (en) 2003-01-21
ID21924A (id) 1999-08-12

Similar Documents

Publication Publication Date Title
CO4900057A1 (es) Dihidrato d de olanzapina
ES2159346T3 (es) Formas cristalinas de un derivado de tieno(2,3-b)(1,5)benzodiazepina y procedimiento para su preparacion.
IS4147A (is) Aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum
DK0447891T3 (da) Thieno(2,3-d)pyrimidinderivater
AU4415285A (en) Benzodiazepine derivatives
SI1513846T1 (sl) Postopek za pripravo olanzapina form I
BR9006299A (pt) Valvula de gaveta de quatro vias
DK0733634T3 (da) Fremgangsmåde til fremstilling af et thieno(2,3-b) (1,5)benzodiazepinderivat
NO982843D0 (no) 2,7-Substituerte oktahydro-pyrrol£1,2-a|pyrazin-derivater
GR1002883B (el) Νεα παραγωγα της 2, 3-βενζοδιαζεπινης
AU1373097A (en) New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
ES2152379T3 (es) Dihidropiridinas condensadas y su utilizacion para la produccion de preparados farmaceuticos.
ZA985211B (en) Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
ES2160308T3 (es) Nuevos derivados amino-metil-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
SI1669359T1 (sl) Postopek za pripravo olanzapina in intermediat zanj
FI973644A0 (fi) Uusi menetelmä 2,3-dihydrobentsofuranolijohdannaisten valmistamiseksi
DE69707293D1 (de) Pyrrolo(3,2-c)chinolin-derivate
FI940607A0 (fi) Imidatso(5,1-C)(1,4)bentsoksatsin-1-onijohdannaiset 5HT3-antagonisteina
ES2159742T3 (es) Procedimiento para la sintesis de benzo(b)tiofenos.
BR9612302A (pt) Tieno [2,3-b]-pirazolo [3,4-d]piridin-3-onas par melhorar a eritropoiese
HUP0003046A3 (en) Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives for the inhibition of farnesyl protein transferase
HK1049668A1 (en) New process for the synthesis of (3as)-5,5-dioxo-2,3,3a,4-tetrahydro-1h-pyrroloÄ2,1-cÜÄ1,2,4Übenzohiadiazine.
ECSP961694A (es) Procedimeinto para preparar olanzapina (caso x - 9992m)
FI923267A (fi) Dekahydro-8h-isokino(2,1-g) (1,6)naftyridin- och dekahydrobenso(a)pyrrolo(2,3-e)-kinolizinderivat
TNSN90138A1 (fr) Procede de preparation de nouveaux derives du selenophene